In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals
Antimicrobial Agents and Chemotherapy · 06.03.2024 · 68 (3)
DOI: 10.1128/aac.01258-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.03.2024. Verfasst von Alina Iovleva und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Azabicyclo Compounds. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIAID NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC 50 /MIC 90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
- Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.
- Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
- Center for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA.
- Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
ORCID-Profile: Cesar A Arias, Carol Hill, Robin Patel, David van Duin, Robert A Bonomo, Yohei Doi
Förderung
- NCATS NIH HHS
- NIAID NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Iovleva, A., McElheny, C. L., Fowler, E. L., Cober, E., Herc, E. S., Arias, C. A., Hill, C., Baum, K., Fowler, V. G., Chambers, H. F., Greenwood-Quaintance, K. E., Patel, R., van Duin, D., Bonomo, R. A., & Doi, Y. (2024). In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrobial Agents and Chemotherapy, 68(3). https://doi.org/10.1128/aac.01258-23
Vancouver
Iovleva A, McElheny CL, Fowler EL, Cober E, Herc ES, Arias CA, et al. In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrobial Agents and Chemotherapy. 2024;68(3). doi:10.1128/aac.01258-23
BibTeX
@article{Iovleva2024,
author = {Iovleva, Alina and McElheny, Christi L and Fowler, Erin L and Cober, Eric and Herc, Erica S and Arias, Cesar A and Hill, Carol and Baum, Keri and Fowler, Vance G and Chambers, Henry F and Greenwood-Quaintance, Kerryl E and Patel, Robin and van Duin, David and Bonomo, Robert A and Doi, Yohei},
title = {In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {3},
doi = {10.1128/aac.01258-23}
}
EUVIMED